

## Beyond the Guidelines: Clinical Investigator Perspectives on the Management of HER2-Low Breast Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. The Phase III DESTINY-Breast06 trial is evaluating trastuzumab deruxtecan (T-DXd) compared to chemotherapy for patients with metastatic HR-positive breast cancer and which of the following HER2 subtypes?**
  - HER2-positive
  - HER2-low
  - HER2 ultra-low
  - Both HER2-positive and HER2-low
  - Both HER2-low and HER2 ultra-low
- 2. Which of the following outcomes best describes the efficacy of T-DXd for patients with advanced HER2-low breast cancer in the Phase III DESTINY-Breast04 trial?**
  - Benefit was significantly greater in the immunohistochemistry (IHC) 1+ population
  - Benefit was significantly greater in the IHC 2+ population
  - Benefit was similar in the IHC 1+ and IHC 2+ populations
- 3. What is the appropriate course of action if a patient receiving T-DXd experiences Grade 3 or Grade 4 interstitial lung disease (ILD)?**
  - Reduce dose but continue therapy
  - Hold dose and restart at a lower dose after symptom resolution
  - Permanently discontinue therapy
- 4. Based on immunostains for HER2, how is the definition of HER2-low best characterized?**
  - IHC 0
  - IHC 1+ and IHC 2+ that is in situ hybridization amplification negative
  - IHC 3+
- 5. HER2-low metastatic breast cancer (mBC) is more commonly observed among which of the following populations?**
  - Patients with ER-negative mBC
  - Patients with ER-positive mBC
  - Low HER2 expression is equally common among patients with ER-negative and ER-positive disease